|
|
|
February 6, 2009
ROXRO Announces FDA Accepts for Review NDA for ROX-888 for the Management of Acute Moderate to Severe Pain
ROXRO PHARMA, Inc. is a late-stage specialty pharmaceutical company developing hospital strength acute pain products for convenient use by patients in the home setting. ROX-888, the company’s lead product, is a novel, investigational intranasal formulation of the potent non-steroidal anti-inflammatory drug (NSAID) ketorolac. Based on clinical studies conducted to date, ROX-888 is expected to allow patients to receive the same benefits of hospital-strength ketorolac in a convenient form. Formulated as an easy-to-use spray, ROX-888 is rapidly absorbed through the nasal mucosa, achieving peak blood levels as fast as an intramuscular injection. ROXRO recently announced that the FDA accepted for review the NDA for ROX-888. Read more here.
--------------------------------
Back to News
|
|
| |
